KRYS — Krystal Biotech

Krystal Biotech (KRYS) — 7-10yr sleeve. VYJUVEK (beremagene geperpavec) is the first and only redosable topical gene therapy for dystrophic epidermolysis bullosa, a rare inherited skin disease with no prior disease-modifying treatment option. The framework’s thesis rests on orphan-disease monopoly structure: a clearly defined patient population, chronic dosing, no approved alternative, and a product relationship that can recur over time rather than resolve through a single administration. Competitive context: displacement risk is limited by VYJUVEK’s approved status, tolerability, redosability, and first-mover position, while the HSV-1 platform creates optionality beyond DEB. Sleeve assignment reflects an approved commercial franchise, strong revenue visibility, internal manufacturing control, and reduced binary dependence relative to earlier-stage gene therapy companies. Named risk: the US DEB patient ceiling limits domestic growth, making international expansion and platform execution the key variables for long-duration compounding.

The BioCompound is a research publication. Nothing here constitutes investment advice.